612 related articles for article (PubMed ID: 27761756)
21. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
22. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
23. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
24. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
25. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
[TBL] [Abstract][Full Text] [Related]
29. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
30. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract][Full Text] [Related]
32. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
33. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
[TBL] [Abstract][Full Text] [Related]
34. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
[TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
[TBL] [Abstract][Full Text] [Related]
36. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
39. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration.
Wang Z; Griffin M
PLoS One; 2013; 8(3):e57017. PubMed ID: 23469180
[TBL] [Abstract][Full Text] [Related]
40. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
